Pharmacoeconomics of immunoglobulins in primary immunodeficiency

References

• Membe SK, Ho C, Cimon K, Morrison A, Kanani A, Roifman CM. Economic assessment of different modalities of immunoglobulin replacement therapy. Immunol. Allergy Clin. North Am.28(4), 861–874 (2008).
   PubMed Web of Science ®Google Scholar
• Durandy A, Wahn V, Petteway S, Gelfand EW. Immunoglobulin replacement therapy in primary antibody deficiency diseases – maximizing success. Int. Arch. Allergy Immunol.136(3), 217–229 (2005).
   PubMed Web of Science ®Google Scholar
• Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs21(2), 105–116 (2007).
   PubMed Web of Science ®Google Scholar
• Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur. J. Health Econ.6(1), 24–29 (2005).
   PubMedGoogle Scholar
• Kallenberg CGM, Laseur M. Cost considerations in choosing an intravenous immunoglobulin preparation. Eur. J. Hosp. Pharm. Pract.13(2), 6–7 (2007).
   Google Scholar
• Kumar A, Teuber SS, Gershwin ME. Intravenous immunoglobulin: striving for appropriate use. Int. Arch. Allergy Immunol.140(3), 185–198 (2006).
   PubMed Web of Science ®Google Scholar
• Liu Z, Albon E, Hyde C. The effectiveness and cost effectiveness of immunoglobulin replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic review and economic evaluation. Department of Public Health and Epidemiology, University of Birmingham, AL, USA (2005).
   Google Scholar
• Orange JS, Hossny EM, Weiler CR et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol.117(4 Suppl.), S525–S553 (2006).
   PubMed Web of Science ®Google Scholar
• Kallenberg CG. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency. Clin. Exp. Immunol.150(3), 437–441 (2007).
   PubMed Web of Science ®Google Scholar
• Mahadevia PJ, Strell J, Kunaprayoon D, Gelfand E. Cost savings from intravenous immunoglobulin manufactured from chromotography/caprylate (Igiv-c) in persons with primary humoral immunodeficiency disorder. Value Health8(4), 488–494 (2005).
   PubMed Web of Science ®Google Scholar
• Gardulf A, Andersen V, Bjorkander J et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet345(8946), 365–369 (1995).
   PubMed Web of Science ®Google Scholar
• Haddad L, Perrinet M, Parent D et al. Étude comparative du coût du traitement à domicile des immunoglobulines intraveineuses ou sous-cutanées a visée substitutive. Revue Méd. Interne27(12), 924–926 (2006).
   PubMed Web of Science ®Google Scholar
• Fasth A, Nystrom J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J. Clin. Immunol.28(4), 370–378 (2008).
   PubMed Web of Science ®Google Scholar
• Wiles CM, Brown P, Chapel H et al. Intravenous immunoglobulin in neurological disease: a specialist review. J. Neurol. Neurosurg. Psychiatr.72, 440–448 (2002).
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford, UK (2005).
   Google Scholar
• Simoens S. Using the Delphi technique in economic evaluation: time to revisit the oracle? J. Clin. Pharm. Ther.31(6), 519–522 (2006).
   PubMed Web of Science ®Google Scholar
• Buchacher A, Iberer G. Purification of intravenous immunoglobulin G from human plasma – aspects of yield and virus safety. Biotechnol. J.1(2), 148–163 (2006).
   PubMedGoogle Scholar
• Constantine MM, Thomas W, Whitman L et al. Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group. Transfusion47(11), 2072–2080 (2007).
   PubMed Web of Science ®Google Scholar
• Pendergrast JM, Sher GD, Callum JL. Changes in intravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995–2000. Vox Sang.89(3), 150–160 (2005).
   PubMed Web of Science ®Google Scholar
• Boulis A, Goold S, Ubel PA. Responding to the immunoglobulin shortage: a case study. J. Health Polit. Policy Law27(6), 977–999 (2002).
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. Intravenous immunoglobulin: Medicare payment and availability. Department of Health and Human Services. Baltimore, MD, USA (2009).
   Google Scholar
• Farrugia A, Poulis P. Intravenous immunoglobulin: regulatory perspectives on use and supply. Transfus. Med.11(2), 63–74 (2001).
   PubMed Web of Science ®Google Scholar
• Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin – reasons and possible solutions. Nat. Clin. Pract. Neurol.3(3), 120–121 (2007).
   PubMedGoogle Scholar
• Provan D, Chapel HM, Sewell WA, O’Shaughnessy D. Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. BMJ337, a1831 (2008).
   Google Scholar
• Chen C, Danekas LH, Ratko TA, Vlasses PH, Matuszewski KA. A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann. Pharmacother.34(3), 295–299 (2000).
   PubMed Web of Science ®Google Scholar
• Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion46(5), 741–753 (2006).
   PubMed Web of Science ®Google Scholar